Inscription Capital LLC Acquires New Shares in Thermo Fisher Scientific Inc. (NYSE:TMO)

Inscription Capital LLC bought a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,037 shares of the medical research company's stock, valued at approximately $516,000.

Several other hedge funds have also recently modified their holdings of TMO. Blackston Financial Advisory Group LLC boosted its position in Thermo Fisher Scientific by 16.4% during the 1st quarter. Blackston Financial Advisory Group LLC now owns 1,234 shares of the medical research company's stock valued at $614,000 after acquiring an additional 174 shares in the last quarter. Grove Bank & Trust boosted its position in Thermo Fisher Scientific by 2.1% during the first quarter. Grove Bank & Trust now owns 6,290 shares of the medical research company's stock valued at $3,130,000 after purchasing an additional 132 shares in the last quarter. Grimes & Company Inc. grew its stake in Thermo Fisher Scientific by 11.2% in the first quarter. Grimes & Company Inc. now owns 15,999 shares of the medical research company's stock valued at $7,961,000 after purchasing an additional 1,609 shares during the last quarter. Community Trust & Investment Co. lifted its position in shares of Thermo Fisher Scientific by 1.7% during the first quarter. Community Trust & Investment Co. now owns 33,945 shares of the medical research company's stock valued at $16,891,000 after buying an additional 557 shares during the last quarter. Finally, QRG Capital Management Inc. boosted its holdings in shares of Thermo Fisher Scientific by 17.5% in the 1st quarter. QRG Capital Management Inc. now owns 44,807 shares of the medical research company's stock valued at $22,296,000 after buying an additional 6,670 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.33% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Robert W. Baird lowered their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Argus lowered their price objective on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a research report on Tuesday, April 29th. The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the company a "buy" rating in a research report on Wednesday, April 23rd. Wells Fargo & Company dropped their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Finally, Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Wednesday, May 21st. Four investment analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $605.30.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $390.17 on Wednesday. The company has a market capitalization of $147.29 billion, a P/E ratio of 22.88, a P/E/G ratio of 2.14 and a beta of 0.78. The business's 50-day moving average is $415.31 and its two-hundred day moving average is $490.41. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $389.86 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period last year, the company earned $5.11 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up .2% compared to the same quarter last year. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.